We present a case report of a patient who received adjuvant carboplatin for stage 1 seminoma and relapsed with abdominal lymph node metastasis at 48 months. In recent years, many oncologists have offered a single cycle of adjuvant carboplatin AUC7 as adjuvant treatment for stage 1 seminoma. The available data show a non-inferior relapse-free survival at 3 years compared with para-aortic radiotherapy. The rate of relapse beyond this point has not been reported. Patients with stage 1 seminoma represent a group of patients with excellent outcomes, and treatment options must also consider the late effects of treatment, of which there are increasing data of mortality for those treated with radiotherapy. Patients who opt for surveillance have a greater than 80% chance of remaining relapse free at 5 years, but those on surveillance require more CT examinations for follow-up. For those treated with single-agent carboplatin, our case report highlights that late relapse can occur, and we suggest that CT surveillance beyond 2 years is required given the lack of mature data on late relapse.

1.
Oliver RDT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP: Radiotherapy versus single dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005;366:293–300.
2.
Aparicio J, Garcia del Muro X, Marato P, Paz-Ares L, Alba E, Saenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sanchez M, Fernandez A, Sastre J, Carles J, Dorca J, Guma J, Yuste AL, Germa JR: Multicentre study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single agent carboplatin for patients with clinical stage I disease. Ann Oncol 2003;14:867–872.
3.
Warde P, Spect L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H: Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:448–452.
4.
Aparicio J, Germa JR, Garcia del Muro X, Maroto P, Arranz JA, Saenz A, Barnadas A, Dorca J, Guma J, Olmos D, Bastus R, Carles J, Almenar D, Sanchez M, Paz-Ares L, Satrustegui JJ, Mellado B, Balil A, Sanchez A: Risk adapted management for patients with clinical stage I seminoma: the second Spanish Germ Cell Cancer Cooperative Group Study. J Clin Oncol 2005;23:8717–8723.
5.
Josefsen D, Fossa S: Management strategies for stage I seminoma. Clin Oncol 2005;17:539–542.
6.
Niazi TM, Souhami L, Sultanem K, Duclos M, Shenouda G, Freeman C: Long-term results of para-aortic radiotherapy for patients with stage I seminoma of the testis. Int J Radiat Oncol Biol Phys 2005;61:741–744.
7.
Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen Fe, Kohler BA, Pukkala E, Lynch CF, Anderson M, Bergfeldt K, Clarke EA, Wilklund T, Gospodarowicz M, Sturgeon J, Fraumeni JF, Boice JD: Risk of second malignant neoplasm among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–1439.
8.
Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnley DP: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513–1523.
9.
Zagars GK, Ballo MT, Lee AK, Strom SS: Mortality after cure of testicular seminoma. J Clin Oncol 2004;22:640–647.
10.
Reiter WJ, Brodowicz T, Alavi S, Zielinski CC, Kozak W, Maier U, Nost G, Lipsky H, Marberger M, Kratzik C: Twelve year experience with two courses of single agent carboplatin for clinical stage I disease. J Clin Oncol 2001;19:101–104.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.